Lentiviruses

Advancing the long-term well-being of people living with HIV

Retrieved on:

Wednesday, July 21, 2021

Retroviridae, HIV, Lentiviruses, Medical specialties, Health, National Minority AIDS Council, HIV/AIDS

People living with HIV are now expected to live nearly as long as people without HIV.

Key Points:

People living with HIV are now expected to live nearly as long as people without HIV.
Despite these advances, those living with HIV often report poor well-being and health-related quality of life.
Following a rigorous, multi-stage Delphi process, the research team established a diverse panel of experts with expertise in the long-term health needs of people living with HIV.
"The field of HIV implementation science can play a key role in assessing the impact of strategies integrated into HIV service delivery to mitigate these issues.

First Trust Senior Floating Rate 2022 Target Term Fund Decreases its Monthly Common Share Distribution to $0.0078 Per Share for August

Retrieved on:

Tuesday, July 20, 2021

Other Professional Services, Professional services, Finance, Finance, Money, Economy, Financial ratios, Animal virology, Feline immunodeficiency virus, Lentiviruses, Rate of return

First Trust Senior Floating Rate 2022 Target Term Fund (the "Fund") (NYSE: FIV) has decreased its regularly scheduled monthly common share distribution to $0.0078 per share from $0.0103 per share. The distribution will be payable on August 16, 2021, to shareholders of record as of August 3, 2021. The ex-dividend date is expected to be August 2, 2021. The monthly distribution information for the Fund appears below.

Key Points:

First Trust Senior Floating Rate 2022 Target Term Fund (the "Fund") (NYSE: FIV) has decreased its regularly scheduled monthly common share distribution to $0.0078 per share from $0.0103 per share.
"Managed Assets" means the total asset value of the Fund minus the sum of its liabilities, other than the principal amount of borrowings.
As a result, based on current market conditions and expectations, the Fund believes that it is unlikely to achieve its objective of returning $9.85 per Common Share upon its termination.
As a result of these actions, investors should anticipate periodic reductions in the Fund's distribution per share going forward.

Gliknik Inc. Raises $11.5 Million in Series C Financing

Retrieved on:

Thursday, June 24, 2021

Research, Infectious diseases, Genetics, Clinical trials, Biotechnology, Health, Pharmaceutical, Science, Oncology, Animal virology, Feline immunodeficiency virus, Lentiviruses, Placebo-controlled study, Immunology, Health sciences, Health, Medicine

Gliknik Inc. , an immunology company dedicated to patients with cancer and autoimmune disorders, today announced that it has successfully completed an $11.5 million Series C Preferred Stock financing.

Key Points:

Gliknik Inc. , an immunology company dedicated to patients with cancer and autoimmune disorders, today announced that it has successfully completed an $11.5 million Series C Preferred Stock financing.
First In Ventures (FIV) led the Series C with SAISO Partners and affiliates of RDA Ventures and Garden Street Holdings also participating.
We believe that Gliknik has created several potential best-in-class mid-stage assets, said Scott Roth, managing partner of FIV.
Funding will help advance Gliknik clinical and pre-clinical programs, including:
A randomized double-blind, placebo-controlled phase 2 study of Gliknik immuno-oncology compound biropepimut-S , which is nearing completion.

First Trust Senior Floating Rate 2022 Target Term Fund Declares its Monthly Common Share Distribution of $0.0103 Per Share for June

Retrieved on:

Thursday, May 20, 2021

Professional services, Finance, Animal virology, Feline immunodeficiency virus, Lentiviruses, Investment management

b'First Trust Senior Floating Rate 2022 Target Term Fund (the "Fund") (NYSE: FIV) has declared the Fund\xe2\x80\x99s regularly scheduled monthly common share distribution in the amount of $0.0103 per share payable on June 15, 2021, to shareholders of record as of June 2, 2021.

Key Points:

b'First Trust Senior Floating Rate 2022 Target Term Fund (the "Fund") (NYSE: FIV) has declared the Fund\xe2\x80\x99s regularly scheduled monthly common share distribution in the amount of $0.0103 per share payable on June 15, 2021, to shareholders of record as of June 2, 2021.
"Managed Assets" means the total asset value of the Fund minus the sum of its liabilities, other than the principal amount of borrowings.
As a result, based on current market conditions and expectations, the Fund believes that it is unlikely to achieve its objective of returning $9.85 per Common Share upon its termination.
The Fund may not be able to reinvest the proceeds received on terms as favorable as the prepaid loan.

A Promising Approach To HIV Cell Therapy, With Exciting Preliminary Results, Was Presented Recently At The Leading Conference On Gene And Cell Therapy

Retrieved on:

Wednesday, May 12, 2021

Branches of biology, Biology, Life sciences, HIV, Lentiviruses, Cell therapy

The patient showed promising results when treated with this new novel cell therapy approach.\n"Great advances have been made in the treatment of many disease states including HIV, with immune-based therapies," says Dr. Phillip Musikanth, HIV specialist and Medical Director of Seraph Medical.

Key Points:

The patient showed promising results when treated with this new novel cell therapy approach.\n"Great advances have been made in the treatment of many disease states including HIV, with immune-based therapies," says Dr. Phillip Musikanth, HIV specialist and Medical Director of Seraph Medical.
"We have yet to master eliminating HIV from the human host.
Our novel approach here offers some new insights to try and achieve this goal by applying immune-based strategies.
Serhat Gumruku (Dr. Serhat) is the Executive Director and Director of Translational Research at the Seraph Research Institute, based in Los Angeles.

LA-Based Research Scientist Introduces Novel COVID-19 Prevention And Cure Strategy

Retrieved on:

Tuesday, March 23, 2021

Branches of biology, HIV, Lentiviruses, Retrovirus, Conference on Retroviruses and Opportunistic Infections, Biology

"My research focuses on eradicating COVID-19, using components already existing within the virus," says Dr. Serhat.

Key Points:

"My research focuses on eradicating COVID-19, using components already existing within the virus," says Dr. Serhat.
Dr. Serhat recently presented his research findings at the 2021 Conference on Retroviruses and Opportunistic Infections (CROI), regarded in the medical research community as the leading HIV and viral research conference in the world.
Dr. Serhat Gumrukcu is the Executive Director and Director of Translational Research at the Seraph Research Institute, based in Los Angeles.
Seraph Research Institute is a non-profit research institution, registered with the U.S. Department of Health and Human Services, that works to advance medical science in the areas of unmet need.

Global Human Immunodeficiency Virus (HIV) Therapeutics Industry to 2029 - Drug Forecast and Market Analysis - ResearchAndMarkets.com

Retrieved on:

Thursday, February 25, 2021

Health, Pharmaceutical, HIV, Lentiviruses, Compound annual growth rate, Academic disciplines, Articles, Medical specialties

The publisher projects that this market will expand at a Compound Annual Growth Rate (CAGR) of 2%, reaching $28B in 2029.

Key Points:

The publisher projects that this market will expand at a Compound Annual Growth Rate (CAGR) of 2%, reaching $28B in 2029.
The long-term efficacy of the pharmacologic management of HIV is highly dependent on patient compliance.
Poor compliance is a risk factor for a shortened life expectancy and greater chance of contracting opportunistic infections.
There will be several drivers that promote growth in the HIV therapeutics market.

Real-World Evidence Study at Miami CFAR Suggests HIV-Associated Wasting Remains an Underappreciated Comorbidity

Retrieved on:

Tuesday, February 9, 2021

HIV/AIDS, HIV, Lentiviruses, Medical specialties

HIV-associated wasting is a condition where HIV+ people taking medication can lose weight and lean body mass without trying and feel a loss of physical endurance.

Key Points:

HIV-associated wasting is a condition where HIV+ people taking medication can lose weight and lean body mass without trying and feel a loss of physical endurance.
The data showed 19.1% (n=2933/15,345) of HIVAW patients were not taking ART, and 17.9% (n=4871/27,242) of HIVAW patients were taking ART.
Additionally, the study revealed that the prevalence of HIV-associated wasting more frequently presented in patients of older age, male gender, history of more comorbidities and opportunistic infections.
Results were shared as an abstract at the Miami CFAR Conference on HIV and Aging in the Era of ART and COVID-19.

ViiV Healthcare receives Marketing Authorisation for Rukobia (fostemsavir), a first-in-class attachment inhibitor in combination with other antiretrovirals for the treatment of adults with multidrug-resistant HIV

Retrieved on:

Monday, February 8, 2021

However, for some people who are living with multidrug-resistant HIV, there is an urgent need for new treatment options.

Key Points:

However, for some people who are living with multidrug-resistant HIV, there is an urgent need for new treatment options.
The Marketing Authorisation for fostemsavir marks a significant milestone, as it addresses a critical unmet need in HIV care for those with little or no treatment options left.
At ViiV Healthcare, through our pioneering research and development, we aim to meet the diverse needs of the HIV community.
We wont stop until our research offers more ways to treat, and hopefully one day, cure HIV.

Mediaplanet and Chef Gabe Bertaccini Bring Awareness to the HIV/AIDS Epidemic

Retrieved on:

Wednesday, December 23, 2020

HIV, Lentiviruses, HIV/AIDS, Medical specialties

This campaign will look to break down the stigma surrounding the virus and highlight new and innovative technologies and therapies in prevention, detection, and treatment.

Key Points:

This campaign will look to break down the stigma surrounding the virus and highlight new and innovative technologies and therapies in prevention, detection, and treatment.
The level of unfamiliarity and misunderstanding surrounding HIV among wide populations has fueled a cloud of ignorance and stigma.
As a result, people have remained ignorant about accurate measures of prevention including getting tested and reaching out to treat and manage the virus.
Our unique ability to pair the right leaders with the right readers, through the right platforms, has made Mediaplanet a global content marketing powerhouse.